Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)

<!DOCTYPE html> <html> <head> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta name="csrf-token" content="xnqgJ3BF93teBAOoCnxOZlHkK6y7BBSd9Nhza0pD"> <meta name="robots" content="noindex, nofollow"> <meta name="msvalidate.01" content="77BC9EC2757BFFD6B08AB6E9830867E2" /> <meta name="msvalidate.01" content="8F0A17F8B7EE136DC522E193ADA44AC2" /> <meta name="msvalidate.01" content="81E0B92D870F20A5A81469EF8E834B59" /> <meta name="msvalidate.01" content="B3D56BE8396E01BC4B5FF1FADDBFEBAC" /> <meta name="msvalidate.01" content="6CF243145B598540D3EBE639EC0CED69" /> <meta name="msvalidate.01" content="5FE75E29938FE1D0DD54BAD2B25C99E4" /> <meta name="msvalidate.01" content="A20920FE8B2693A844693CA7B2DA0341" /> <meta name="msvalidate.01" content="443527962984ED6113E71C2E1C1E6FCC" /> <meta name="msvalidate.01" content="58D49F2458FE6C8E642907D29D522720" /> <meta name="msvalidate.01" content="851D73C3284A97030F2B09FDECBB3AD4" /> <meta name="msvalidate.01" content="A656B1E6BC13BAE9D5A8773D01104738" /> <meta name="msvalidate.01" content="61789A989A2520E21E638DD047CB7332" /> <meta name="msvalidate.01" content="B7C6A3E0D04CC5BA0C608C9520F3D00B" /> <meta name="msvalidate.01" content="F48263C70EDE1DC309187238F96CCE3F" /> <meta name="msvalidate.01" content="0EE0DAA2E0981DF931A252C15FCBCA2C" /> <meta name="msvalidate.01" content="0A07E3A82E7C0D9F9D9C345659EDB9DE" /> <meta name="msvalidate.01" content="131BBB629297ACBB160173ED53395845" /> <meta name="msvalidate.01" content="05555D8659A1D65F7D0E2EBA014AF981" /> <meta name="msvalidate.01" content="78AC6224A015A61918E531E916DD44FA" /> <meta name="msvalidate.01" content="7D606D72FCE39D630B7985DE1F0361B1" /> <meta name="msvalidate.01" content="EF3C401C6A614F8D465A9341CBFC5090" /> <meta name="msvalidate.01" content="EB952236EB778B9340696B13F7353A3D" /> <meta name="msvalidate.01" content="897AEDC10475FB0295F82A4210D64590" /> <meta name="msvalidate.01" content="F430E75F1EF116C6EFA24DE7CB3E0BC9" /> <meta name="msvalidate.01" content="F7B3BD2FE69072BCCE4126B9CC5045CB" /> <meta name="msvalidate.01" content="98EF95AD212ADD48C878F21B193AB8E4" /> <meta name="msvalidate.01" content="7C25DA74C8FF5FAB142FC70204BB07A6" /> <meta name="msvalidate.01" content="1D0E1105D459663D83517C7646FC097D" /> <meta name="msvalidate.01" content="81D4616A768B982EB9CE2018AECAE8F6" /> <meta name="msvalidate.01" content="8A3522EFAF15FC4FDF3B35078C516DB7" /> <meta name="msvalidate.01" content="5D38CFA2B20914936FDB97E2B9FB39C6" /> <meta name="msvalidate.01" content="3BC91AA62DFB93BBB6AF0F324F83B879" /> <meta name="msvalidate.01" content="EF8A373ACF36FCC9C576F7E17BDC0ED0" /> <meta name="msvalidate.01" content="8C25C1EC562A320C4E886F6FBD551AA0" /> <meta name="msvalidate.01" content="4BA3D4BEDFCBDE8D855A5D67FB70ECAD" /> <meta name="msvalidate.01" content="E10CD32B036CAFEE4E0BAF11165F6D14" /> <meta name="msvalidate.01" content="E97FE2DDBEBEE0B3AB82D7D7499D54B0" /> <meta name="msvalidate.01" content="895A1ECBF4F65AB03AB7449235C31DA7" /> <meta name="msvalidate.01" content="F03D9D95ECB8E1D15F5DF466E55DC2EF" /> <meta name="msvalidate.01" content="10D1437BF96D7A042B768C9F7731BAB4" /> <meta name="msvalidate.01" content="7ED6C9C1C31D32B7B13F91DFB3BCB4F7" /> <meta name="msvalidate.01" content="37AF4033FCDC8814D80B3347D8DCFD61" /> <meta name="msvalidate.01" content="14828660C6B43D54B71B032573D1DCC6" /> <meta name="msvalidate.01" content="968272C9D1F17F43A36BEF900C379237" /> <meta name="msvalidate.01" content="752B68F93142732EAB7CCB7A5D776D16" /> <meta name="msvalidate.01" content="B1A99BDD7D6156B30A78E68F365C9F83" /> <meta name="msvalidate.01" content="6C25E85F718295037CD6F2B882C55F0C" /> <meta name="msvalidate.01" content="5C7D771CAF9E1D204A650ACD0E1CCC27" /> <meta name="msvalidate.01" content="0A33808F913B3177D30C05FFEA18A778" /> <meta name="msvalidate.01" content="6A58B74EB884C7D4DFF37B085C2EF641" /> <meta name="msvalidate.01" content="0154F0B163EC39E2C00077A555BB712F" /> <meta name="msvalidate.01" content="78D17C560AC7BBDC345D966938135AD5" /> <meta name="msvalidate.01" content="9DD6BD390FBB5FCE73E03376DF6923C2" /> <meta name="msvalidate.01" content="2BBC0BE30006807810C289BDF64CFF11" /> <meta name="msvalidate.01" content="6EB50B0564B4A30C435A67724D547579" /> <meta name='ir-site-verification-token' value='529231765' /> <meta name='impact-site-verification' value='34bab047-b19c-4a2d-83b9-4e7b91954a89'> <title>Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)</title><meta name="description" content="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approxima..."><meta property="article:published_time" content="2024-12-03T00:57:56+07:00"><meta property="article:modified_time" content="2024-12-03T00:57:56+07:00"><link rel="canonical" href="https://seagamenight.com/article/roche-to-acquire-poseida-therapeutics-advancing-leadership-in-cell-therapy-innovation/8774"/><meta property="og:title" content="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)" /><meta property="og:description" content="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approxima..." /><meta property="og:type" content="article" /><meta property="og:site_name" content="Seagamenight" /><meta property="og:url" content="https://seagamenight.com/article/roche-to-acquire-poseida-therapeutics-advancing-leadership-in-cell-therapy-innovation/8774" /><meta property="og:image" content="https://i0.wp.com/news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-940x367.jpg" /><meta name="twitter:title" content="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)" /><meta name="twitter:description" content="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approxima..." /><meta name="twitter:image" content="https://i0.wp.com/news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-940x367.jpg" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:label1" content="Written by" /><meta name="twitter:data1" content="Greg O'Connell" /><meta name="twitter:label2" content="Est. reading time" /><meta name="twitter:data2" content="3 minutes" /><script type="application/ld+json">{"@context":"https://schema.org","@type":"AggregateRating","name":"Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)","description":"Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approxima...","image":"https://i0.wp.com/news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-940x367.jpg","itemReviewed":{"name":"Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation","@type":"MediaObject"},"ratingValue":4.111111111111111,"ratingCount":42}</script> <link rel="stylesheet" href="/static-res/css/newsike.css?id=3dec9ad9859d5f7df554"> <script src="/static-res/js/newsike.js?id=7f363cc5445f1191888e" defer></script> <link rel="preconnect" href="https://www.googletagmanager.com" /> <link rel="dns-prefetch" href="https://www.googletagmanager.com" /> <link rel="alternate" type="application/rss+xml" href="https://api.mattsonhomes.com/v1/rss"> <link rel="apple-touch-icon" sizes="57x57" href="/static-res/img/newsike/apple-icon-57x57.png?id=7f2dd0f19fc9423ccae5" /> <link rel="apple-touch-icon" sizes="60x60" href="/static-res/img/newsike/apple-icon-60x60.png?id=0bd5f84ce8093a295d08" /> <link rel="apple-touch-icon" sizes="72x72" href="/static-res/img/newsike/apple-icon-72x72.png?id=fed97a82d99287329aa1" /> <link rel="apple-touch-icon" sizes="76x76" href="/static-res/img/newsike/apple-icon-76x76.png?id=8dd2b4bd97e42ce4bb48" /> <link rel="apple-touch-icon" sizes="114x114" href="/static-res/img/newsike/apple-icon-114x114.png?id=e1350d22e08f3a9a98ee" /> <link rel="apple-touch-icon" sizes="120x120" href="/static-res/img/newsike/apple-icon-120x120.png?id=c8f79402edc377935736" /> <link rel="apple-touch-icon" sizes="144x144" href="/static-res/img/newsike/apple-icon-144x144.png?id=e103a4bdcfdaedd66ae6" /> <link rel="apple-touch-icon" sizes="152x152" href="/static-res/img/newsike/apple-icon-152x152.png?id=026787d9b01866dc2ecb" /> <link rel="apple-touch-icon" sizes="180x180" href="/static-res/img/newsike/apple-icon-180x180.png?id=ac5d8669f9fac00716da" /> <link rel="icon" type="image/png" sizes="192x192" href="/static-res/img/newsike/android-icon-192x192.png?id=8de180f7a159494d7e57" /> <link rel="icon" type="image/png" sizes="32x32" href="/static-res/img/newsike/favicon-32x32.png?id=39a6afc44c6afe88283c" /> <link rel="icon" type="image/png" sizes="96x96" href="/static-res/img/newsike/favicon-96x96.png?id=98b4072dae559862b5fc" /> <link rel="icon" type="image/png" sizes="16x16" href="/static-res/img/newsike/favicon-16x16.png?id=a43a5a3c7de4d329262b" /> <link rel="manifest" href="/static-res/img/newsike/manifest.json?id=6d0a109cbc6d45f4e64b"> <meta name="msapplication-TileImage" content="/static-res/img/newsike/ms-icon-144x144.png?id=e103a4bdcfdaedd66ae6" /> <meta name="msapplication-TileColor" content="#ffffff" /> <meta name="theme-color" content="#ffffff" /> <meta http-equiv="x-ua-compatible" content="ie=edge">  <script async src="https://www.googletagmanager.com/gtag/js?id=G-54725HQVMF"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-54725HQVMF'); </script> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script> </head> <body> <time datetime="2024-12-03T00:57:56+07:00"></time> <div x-data="{"show":true,"style":"success","message":null}" :class="{ 'bg-indigo-500': style == 'success', 'bg-red-700': style == 'danger', 'bg-gray-500': style != 'success' && style != 'danger' }" style="display: none;" x-show="show && message" x-init=" document.addEventListener('banner-message', event => { style = event.detail.style; message = event.detail.message; show = true; }); "> <div class="max-w-screen-xl mx-auto py-2 px-3 sm:px-6 lg:px-8"> <div class="flex items-center justify-between flex-wrap"> <div class="w-0 flex-1 flex items-center min-w-0"> <span class="flex p-2 rounded-lg" :class="{ 'bg-indigo-600': style == 'success', 'bg-red-600': style == 'danger' }"> <svg x-show="style == 'success'" class="h-5 w-5 text-white" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z" /> </svg> <svg x-show="style == 'danger'" class="h-5 w-5 text-white" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 8v4m0 4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z" /> </svg> <svg x-show="style != 'success' && style != 'danger'" class="h-5 w-5 text-white" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z" /> </svg> </span> <p class="ml-3 font-medium text-sm text-white truncate" x-text="message"></p> </div> <div class="flex-shrink-0 sm:ml-3"> <button type="button" class="-mr-1 flex p-2 rounded-md focus:outline-none sm:-mr-2 transition" :class="{ 'hover:bg-indigo-600 focus:bg-indigo-600': style == 'success', 'hover:bg-red-600 focus:bg-red-600': style == 'danger' }" aria-label="Dismiss" x-on:click="show = false"> <svg class="h-5 w-5 text-white" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12" /> </svg> </button> </div> </div> </div> </div> <div class="min-h-screen bg-gray-100"> <nav x-data="{ open: false }" class="bg-white">  <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8"> <div class="flex justify-between h-11 sm:h-12"> <div class="flex">  <div class="flex-shrink-0 flex items-center"> <a href="https://seagamenight.com" class="text-xl font-bold tracking-wider text-primary-500"> Seagamenight </a> </div>  <div class="hidden space-x-8 sm:-my-px sm:ml-10 sm:flex"> <a class="inline-flex items-center px-1 pt-1 border-b-2 border-transparent text-sm font-medium leading-5 text-gray-500 hover:text-gray-700 hover:border-gray-300 focus:outline-none focus:text-gray-700 focus:border-gray-300 transition" href="https://seagamenight.com"> Home </a> <a class="inline-flex items-center px-1 pt-1 border-b-2 border-transparent text-sm font-medium leading-5 text-gray-500 hover:text-gray-700 hover:border-gray-300 focus:outline-none focus:text-gray-700 focus:border-gray-300 transition" href="https://seagamenight.com/search-article"> Search </a> <form class="inline-flex items-center w-72 mb-0" action="https://seagamenight.com/search-article" target="_top" > <input aria-label="keyword" type="text" name="keyword" class="ml-4 sm:ml-0 mt-2 sm:mt-0 w-full text-sm rounded-lg border-gray-200 border-solid-x" placeholder="Search..." /> </form> </div> </div>  <div class="-mr-2 flex items-center sm:hidden"> <button @click="open = ! open" aria-label="menu" class="inline-flex items-center justify-center p-2 rounded-md text-gray-400 hover:text-gray-500 hover:bg-gray-100 focus:outline-none focus:bg-gray-100 focus:text-gray-500 transition"> <svg class="h-6 w-6" stroke="currentColor" fill="none" viewBox="0 0 24 24"> <path :class="{'hidden': open, 'inline-flex': ! open }" class="inline-flex" stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16" /> <path :class="{'hidden': ! open, 'inline-flex': open }" class="hidden" stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12" /> </svg> </button> </div> </div> </div>  <div :class="{'block': open, 'hidden': ! open}" class="hidden sm:hidden"> <div class="pt-2 pb-3 space-y-1"> <a class="block pl-3 pr-4 py-2 border-l-4 border-transparent text-base font-medium text-gray-600 hover:text-gray-800 hover:bg-gray-50 hover:border-gray-300 focus:outline-none focus:text-gray-800 focus:bg-gray-50 focus:border-gray-300 transition" href="https://seagamenight.com"> Home </a> <a class="block pl-3 pr-4 py-2 border-l-4 border-transparent text-base font-medium text-gray-600 hover:text-gray-800 hover:bg-gray-50 hover:border-gray-300 focus:outline-none focus:text-gray-800 focus:bg-gray-50 focus:border-gray-300 transition" href="https://seagamenight.com/search-article"> Search </a> <form class="inline-flex items-center w-72 mb-0" action="https://seagamenight.com/search-article" target="_top" > <input aria-label="keyword" type="text" name="keyword" class="ml-4 sm:ml-0 mt-2 sm:mt-0 w-full text-sm rounded-lg border-gray-200 border-solid-x" placeholder="Search..." /> </form> </div> </div> </nav> <div class="text-center text-center my-0 sm:my-1 " > <ins class="adsbygoogle adsense " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <main class="mt-2 flex"> <div class="text-center sticky top-2 left-2 hidden xl:block flex-shrink-0 " style="width: 160px; height: 600px;" > <ins class="adsbygoogle adsense h-ad4 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <div class="main-container container"> <main class="left-container doc-detail"> <section class="hentry flex items-center md:items-start mt-3 md:mt-3 ml-0 flex-col md:flex-row"> <div class="w-full"> <h1 class="entry-title mb-5 text-center font-semibold text-2xl xl:text-4xl !leading-common"> Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024) </h1> <div class="text-center my-2 sm:my-4 " > <ins class="adsbygoogle adsense h-ad3 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <article class="article-detail"> <section class="entry-content paragraph"><div><div><div><p><span></span></p><p>Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation</p></div><p><span title="IN BRIEF">(IN BRIEF)</span> <strong>Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approximately $1 billion. Poseida stockholders may also receive up to $4.00 per share in contingent milestone payments, potentially bringing the deal’s value to $1.5 billion. This acquisition builds on a 2022 collaboration and enhances Roche’s capabilities in oncology, immunology, and neurology. Poseida’s portfolio includes P-BCMA-ALLO1, an allogeneic CAR-T therapy for multiple myeloma, and other promising cell therapy programs targeting B-cell malignancies, autoimmune diseases, and solid tumors. The deal provides Roche with Poseida’s genomic technology, GMP manufacturing capabilities, and innovative cell therapy expertise. Expected to close in Q1 2025, the transaction reinforces Roche’s commitment to pioneering transformative treatments and expanding its leadership in the cell therapy space.</strong></p><p><span title="PRESS RELEASE">(PRESS RELEASE)</span> BASEL, 27-Nov-2024 — /<span>EuropaWire</span>/ — Roche has entered into a definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies. The acquisition, valued at up to $1.5 billion, reinforces Roche’s strategy to expand its capabilities across oncology, immunology, and neurology by leveraging Poseida’s cutting-edge research and development in cell therapy.<div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></p><p><strong>Acquisition Details</strong></p><p>Under the terms of the agreement, Roche will acquire Poseida for $9.00 per share in cash at closing, representing a total equity value of approximately $1.0 billion. Additionally, Poseida stockholders will receive a contingent value right (CVR) worth up to $4.00 per share in cash, tied to the achievement of clinical and commercial milestones. The transaction, which reflects a 215% premium on Poseida’s recent stock price, is expected to close in Q1 2025, subject to regulatory approvals and customary conditions.</p><p><strong>Strategic Implications</strong></p><p>This acquisition builds on a 2022 collaboration between Roche and Poseida aimed at developing off-the-shelf CAR-T therapies for hematological cancers. It strengthens Roche’s capabilities in creating scalable, highly potent cell therapies that address unmet medical needs across cancer and autoimmune diseases. The integration of Poseida’s GMP manufacturing and cutting-edge genomic technologies will further accelerate Roche’s advancements in this field.</p><p><strong>Poseida’s Key Assets</strong></p><ul><li>P-BCMA-ALLO1: A flagship allogeneic CAR-T therapy targeting multiple myeloma, currently in Phase 1 trials with regulatory designations from the FDA.</li><li>P-CD19CD20-ALLO1: A dual CAR-T therapy for B-cell malignancies, with potential applications in autoimmune diseases like multiple sclerosis and systemic lupus erythematosus.</li><li>P-MUC1C-ALLO1: A CAR-T program in development for solid tumors.</li></ul><p>Poseida’s innovative platform combines novel antigen targeting and dual CAR-T capabilities, promising next-generation therapeutic solutions.</p><p><strong>Roche’s Vision</strong></p><p>“This acquisition aligns with our mission to pioneer transformative therapies,” <strong>said Levi Garraway, Roche’s Head of Product Development</strong>. “Poseida’s expertise complements our portfolio, and we are excited about the potential for these therapies to improve patient outcomes.”</p><p><strong>Aviv Regev, Head of Genentech Research & Early Development, added</strong>: “This collaboration brings cutting-edge technologies and expertise together, maximizing the transformative potential of cell therapy.”</p><p><strong>Transaction Terms</strong><div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></p><p><strong>Poseida’s shareholders stand to gain up to $4.00 per share in contingent milestone payments, including:</strong></p><ul><li>$2.00 per share upon pivotal study initiation for P-BCMA-ALLO1 by 2028.</li><li>$1.00 per share for autoimmune applications of P-CD19CD20-ALLO1 or related products by 2034.</li><li>$1.00 per share upon the first commercial sale of P-BCMA-ALLO1 by 2031.</li></ul><p>The transaction has been unanimously approved by both companies’ boards.<div class="bg-primary-100 rounded-lg my-6 px-2 py-3 font-semibold insert" style="color: rgb(37, 99, 235)"><div class="text-common !leading-common ml-1 insert" style="margin-top: 0.2rem; margin-bottom: 0.2rem">See Also</div><a class="list-item toc-h2 py-1" style="border-bottom: none" href="https://seagamenight.com/article/effects-of-infrared-radiation-on-skin-photo-aging-and-pigmentation/8774" target="_blank" rel="noopener">Effects of Infrared Radiation on Skin Photo-Aging and Pigmentation</a><a class="list-item toc-h2 py-1" style="border-bottom: none" href="https://seagamenight.com/article/a-controlled-trial-to-determine-the-efficacy-of-red-and-near-infrared-light-treatment-in-patient-satisfaction-reduction-of-fine-lines-wrinkles-skin-roughness-and-intradermal-collagen-density-increase/8774" target="_blank" rel="noopener">A Controlled Trial to Determine the Efficacy of Red and Near-Infrared Light Treatment in Patient Satisfaction, Reduction of Fine Lines, Wrinkles, Skin Roughness, and Intradermal Collagen Density Increase</a><a class="list-item toc-h2 py-1" style="border-bottom: none" href="https://seagamenight.com/article/830-nm-light-emitting-diode-led-phototherapy-significantly-reduced-return-to-play-in-injured-university-athletes-a-pilot-study/8774" target="_blank" rel="noopener">830 nm light-emitting diode (led) phototherapy significantly reduced return-to-play in injured university athletes: a pilot study</a><a class="list-item toc-h2 py-1" style="border-bottom: none" href="https://seagamenight.com/article/us-patent-for-solid-drug-form-of-n-2-6-bis-1-methylethyl-phenyl-n-1-4-dimethylamino-phenyl-cyclopentyl-methyl-urea-hydrochloride-and-compositions-methods-and-kits-related-thereto-patent-patent-12-151-998-issued-november-26-2024/8774" target="_blank" rel="noopener">US Patent for Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto Patent (Patent # 12,151,998 issued November 26, 2024)</a></div></p><p><strong>About the Poseida Programmes and Pipeline</strong><br><strong>Assets in the current collaboration:</strong></p><ul><li>The lead programme, P-BCMA-ALLO1, is an allogeneic CAR-T therapy targeting B-cell maturation antigen (BCMA). P-BCMA-ALLO1 has received Regenerative Medicine Advanced Therapy designation for relapsed/refractory multiple myeloma (MM) after three or more prior lines of therapies, and FDA Orphan Drug Designation for MM. Early clinical data have been reported in September at the International Myeloma Society annual meeting (Poseida PR).</li><li>A second clinical programme in Phase 1 is P-CD19CD20-ALLO1, an allogeneic dual CAR-T in B-cell malignancies. Building on the transformative potential of the CAR-T modality beyond oncology, FDA INDs have been recently filed to investigate this programme’s potential for patients with multiple sclerosis and systemic lupus erythematosus.</li><li>An additional allogeneic, dual CAR-T programme targeting known antigens expressed in haematologic malignancies(Poseida PR)has been initiated.</li></ul><p><strong>Upon closing of the transaction, Roche will obtain access to Poseida’s GMP manufacturing capabilities and other R&D portfolio assets, as well as their know-how and expertise, including:</strong></p><ul><li>P-MUC1C-ALLO1, an allogeneic CAR-T programme currently in Phase 1 in solid tumours.</li><li>Genomic medicine pre-clinical candidates as well as related technologies.</li></ul><p>Current Poseida employees will join the Roche Group as part of Roche’s Pharmaceuticals Division.</p><p>“Our interest in cell therapy is directly tied to our commitment to discovering and developing pioneering medicines with substantial patient benefit,” <strong>said Aviv Regev, Head of Genentech Research & Early Development</strong>. “We are excited to bring together cutting-edge scientific approaches and expertise to tap into the full transformative potential of cell therapy.”</p><p><strong>Terms of the Agreement</strong><br>Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all of the outstanding shares of Poseida common stock at a price of US $9.00 per share in cash at closing plus a non-tradeable CVR to receive certain milestone payments of up to an aggregate of US $4.00 per share in cash, representing a total equity value of approximately US $1.0 billion at closing and representing a total deal value of up to US $1.5 billion. The price payable at closing represents a premium of approximately 215% to Poseida’s closing share price on 25 November 2024. The merger agreement has been unanimously approved by the boards of Roche and Poseida.</p><p>Poseida will file a recommendation statement containing the unanimous recommendation of the Poseida board that Poseida’s stockholders tender their shares pursuant to the tender offer. Following the completion of the tender offer, Roche will acquire all remaining shares at the same price of US $9.00 per share in cash through a second step merger.</p><p><strong>Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments, conditioned upon the achievement of certain clinical development and commercial milestones, within specified time periods:</strong></p><ol><li>US $2.00 per share in cash, upon the initiation of the first pivotal study of a P-BCMA-ALLO1 product for the treatment of any indication (by December 31, 2028)</li><li>US $1.00 per share in cash, upon the initiation of the first pivotal study of a P-CD19CD20-ALLO1 product or of a P-BCMACD19-ALLO1 product for the treatment of an autoimmune indication (by December 31, 2034)</li><li>US $1.00 per share in cash, upon the first commercial sale of a P-BCMA-ALLO1 product for the treatment of any indication (by December 31, 2031)</li></ol><p>There can be no assurance that any payments will be made with respect to the CVR. Assuming the conditions of the CVR are met, this would represent an additional cash consideration of up to approximately US $0.5 billion for Poseida’s stockholders.<div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></p><p>The transaction is expected to close in the first quarter of 2025 and is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Poseida’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</p><p>Citi is acting as exclusive financial advisor to Roche and Sidley Austin LLP is acting as legal counsel to Roche. Centerview Partners LLC is acting as exclusive financial advisor to Poseida and Cooley LLP is acting as legal counsel to Poseida.</p><p><strong>About Poseida</strong><br>Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumours, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company’s approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients.</p><p><strong>About Roche</strong><br>Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.</p><p>For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.</p><p>Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.</p><p>For more information, please visit<a href="http://www.roche.com" rel="noopener nofollow" target="_blank" title="">www.roche.com</a>.</p><p>All trademarks used or mentioned in this release are protected by law.</p><p><strong>IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT</strong></p><p>The tender offer for the outstanding shares of common stock of Poseida has not yet commenced. This announcement is for informational purposes only and does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Poseida’s securities. The solicitation and offer to purchase Poseida’s common stock will only be made pursuant to an offer to purchase and related tender offer materials. At the time the tender offer is commenced, Roche Holdings, Inc. (“Roche”) and its acquisition subsidiary, a wholly owned subsidiary of Roche, will file a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the “SEC”) and thereafter, Poseida will file a Solicitation/Recommendation Statement on Schedule 14d-9 with the SEC with respect to the tender offer. The tender offer materials (including the Offer to Purchase, a related Letter of Transmittal and other tender offer documents) and the Solicitation/Recommendation Statement on Schedule 14d-9 will contain important information.<div class="bg-primary-100 rounded-lg my-6 px-2 py-3 font-semibold insert" style="color: rgb(37, 99, 235)"><div class="text-common !leading-common ml-1 insert" style="margin-top: 0.2rem; margin-bottom: 0.2rem">See Also</div><a class="list-item toc-h2 py-1" style="border-bottom: none" href="https://seagamenight.com/article/clinical-features-and-risk-factors-of-klebsiella-pneumoniae-infection-in-premature-infants-a-retrospective-cohort-study/8774" target="_blank" rel="noopener">Clinical features and risk factors of Klebsiella pneumoniae infection in premature infants: a retrospective cohort study</a></div><div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></p><p>INVESTORS AND STOCKHOLDERS ARE URGED TO READ THESE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS MAY BE AMENDED FROM TIME TO TIME, CAREFULLY WHEN THEY BECOME AVAILABLE PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES IN THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.</p><p>The tender offer materials and the Solicitation/Recommendation Statement will be filed with the SEC, and investors and stockholders may obtain a free copy of these materials (when available) and other documents filed by Roche and Poseida with the SEC at the website maintained by the SEC at www.sec.gov. Free copies of the offer to purchase, the related letter of transmittal and certain other offering documents will be made available by Parent and when available may be obtained by directing a request to the Information Agent for the tender offer which will be named in the Tender Offer Statement on Schedule TO. Investors and stockholders may also obtain free copies of the documents filed with the SEC by Poseida on the investor relations page of Poseida’s internet website at https://investors.poseida.com.</p><p><strong>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This communication may include statements that are not statements of historical fact, or “forward-looking statements,” within the meaning of the federal securities laws, including with respect to Roche’s proposed acquisition of Poseida. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. These statements are generally identified by words or phrases such as “believe”, “anticipate”, “expect”, “intend”, “plan”, “will”, “may”, “should”, “estimate”, “predict”, “project”, “strategy”, “potential”, “continue” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, the ability of Roche and Poseida to complete the transactions contemplated by the merger agreement, including each party’s ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement, statements about the expected timetable for completing the transaction, the parties’ beliefs and expectations and statements about the benefits sought to be achieved in Roche’s proposed acquisition of Poseida, the potential effects of the acquisition on both Roche and Poseida and the possibility of any termination of the merger agreement. These statements are based upon the current beliefs and expectations of Roche and Poseida’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable if at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements, and you should not place undue reliance on these statements.</p><p>Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Poseida’s stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the offer and the merger contemplated by the merger agreement may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the tender offer or the subsequent merger; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Poseida’s business; the possibility that the milestone payments related to the contingent value right will never be achieved and that no milestone payment may be made; and the risk of legal proceedings being brought in relation to the transactions and the outcome of such proceedings, including the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Poseida’s public filings with the SEC, including the “Risk Factors” section of Poseida’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q, Form 8-K and in other filings Poseida makes with the SEC from time to time as well as the tender offer materials to be filed by Roche and its acquisition subsidiary and the Solicitation/Recommendation Statement to be filed by Poseida, in each case as amended by any subsequent filings made with the SEC.</p><p>Neither Roche nor Poseida undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.</p><p><strong>Media Contacts:</strong></p><p>Roche Global Media Relations<br>Phone: +41 61 688 8888 / e-mail: media.relations@roche.com</p><table><tbody><tr><td>Hans Trees, PhD<br>Phone: +41 79 407 72 58</td><td>Sileia Urech<br>Phone: +41 79 935 81 48</td></tr><tr><td>Nathalie Altermatt<br>Phone: +41 79 771 05 25</td><td>Lorena Corfas<br>Phone: +41 79 568 24 95</td></tr><tr><td>Simon Goldsborough<br>Phone: +44 797 32 72 915</td><td>Karsten Kleine<br>Phone: +41 79 461 86 83</td></tr><tr><td>Nina Mählitz<br>Phone: +41 79 327 54 74</td><td>Kirti Pandey<br>Phone: +49 172 6367262</td></tr><tr><td>Yvette Petillon<br>Phone: +41 79 961 92 50</td><td>Dr Rebekka Schnell<br>Phone: +41 79 205 27 03</td></tr></tbody></table><p>Roche Investor Relations</p><table><tbody><tr><td>Dr Bruno Eschli<br>Phone: +41 61 68-75284<br>e-mail: bruno.eschli@roche.com</td><td>Dr Sabine Borngräber<br>Phone: +41 61 68-88027<br>e-mail:<span>sabine.borngraeber@roche.com</span></td></tr><tr><td>Dr Birgit Masjost<br>Phone: +41 61 68-84814<br>e-mail: birgit.masjost@roche.com</td><td></td></tr></tbody></table><p>Investor Relations North America<div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></p><table><tbody><tr><td>Loren Kalm<br>Phone: +1 650 225 3217<br>e-mail: kalm.loren@gene.com</td><td></td></tr></tbody></table><p>SOURCE: Roche</p><div><p><strong>MORE ON ROCHE, ETC.:</strong></p><ul><li><div><p><span>Roche's SKYSCRAPER-01 Study: Update on Tiragolumab's Role in Advanced Lung Cancer Therapy</span></p></div></li><li><div><p><span>Roche's Itovebi Regimen Shows Significant Survival Benefits for HR-Positive Breast Cancer in Phase III Trial Results</span></p></div></li><li><div><p><span>Roche Showcases Advancements in Alzheimer’s Diagnostics at CTAD 2024</span></p></div></li><li><div><p><span>University of Liverpool and Roche Diagnostics Unite to Drive Health Innovation and Address Inequalities</span></p><div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></div></li><li><div><p><span>Roche’s Evrysdi Shows Remarkable Motor and Cognitive Outcomes in Children with SMA After Two Years of Early Treatment</span></p></div></li><li><div><p><span>Roche Secures CE Certification for Groundbreaking Companion Diagnostic Aiding Gastric Cancer Treatment</span></p></div></li><li><div><p><span>Roche’s Gazyva Shows Breakthrough Results in Treating Lupus Nephritis, Offering Hope for Kidney Disease Patients</span></p></div></li><li><div><p><span>Roche's PiaSky Approved in EU as First Monthly Self-Administered Treatment for PNH</span></p></div></li><li><div><p><span>Roche Launches Advanced Diagnostic Test for B-Cell Lymphoma Detection</span></p><div class="sm:flex sm:items-center sm:justify-center sm:flex-row sm:space-x-1 insert" style="margin-top:0; margin-bottom:0;"><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script><ins class="adsbygoogle sm:w-1/2" style="display:block; text-align:center;" data-ad-layout="in-article" data-ad-format="fluid" data-full-width-responsive="true" data-ad-slot="5425269451" data-ad-client="ca-pub-2100455203284867" data-adtest="off"></ins><script>(adsbygoogle = window.adsbygoogle || []).push({});</script></div></div></li></ul></div><p><a href="https://news.google.com/publications/CAAqBwgKMNuVlQsw1PSqAw?ceid=US:en&oc=3" rel="noopener nofollow" target="_blank"><img alt="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2)" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" referrerpolicy="no-referrer" title="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2)" data-src="https://i0.wp.com/news.europawire.eu/wp-content/uploads/2023/12/follow-EuropaWire-on-google-news-icon-1.png" data-src2="https://news.europawire.eu/wp-content/uploads/2023/12/follow-EuropaWire-on-google-news-icon-1.png" onerror="if(this.src==this.getAttribute('data-src2')){onImageError(this,true)}else{this.src=this.getAttribute('data-src2')}"></a></p><div><p><strong>EDITOR'S PICK:</strong></p><ul> <li><span>New IDTechEx Report Predicts Regulatory Shifts Will Transform the Electric Light Commercial Vehicle Market</span></li><li><span>Almost 1 in 4 Planes Sold in 2045 to be Battery Electric, Finds IDTechEx Sustainable Aviation Market Report</span></li><li><span>Digi Communications N.V. announces the release of Q3 2024 financial results</span></li><li><span>Digi Communications NV announces Investors Call for the presentation of the Q3 2024 Financial Results</span></li><li><span>Pilot and Electriq Global announce collaboration to explore deployment of proprietary hydrogen transport, storage and power generation technology</span></li><li><span>Digi Communications N.V. announces the conclusion of a Memorandum of Understanding by its subsidiary in Romania</span></li><li><span>Digi Communications N.V. announces that the Company’s Portuguese subsidiary finalised the transaction with LORCA JVCO Limited</span></li><li><span>Digi Communications N.V. announces that the Portuguese Competition Authority has granted clearance for the share purchase agreement concluded by the Company’s subsidiary in Portugal</span></li><li><span>OMRON Healthcare introduceert nieuwe bloeddrukmeters met AI-aangedreven AFib-detectietechnologie; lancering in Europa september 2024</span></li><li><span>OMRON Healthcare dévoile de nouveaux tensiomètres dotés d’une technologie de détection de la fibrillation auriculaire alimentée par l’IA, lancés en Europe en septembre 2024</span></li><li><span>OMRON Healthcare presenta i nuovi misuratori della pressione sanguigna con tecnologia di rilevamento della fibrillazione atriale (AFib) basata sull’IA, in arrivo in Europa a settembre 2024</span></li><li><span>OMRON Healthcare presenta los nuevos tensiómetros con tecnología de detección de fibrilación auricular (FA) e inteligencia artificial (IA), que se lanzarán en Europa en septiembre de 2024</span></li><li><span>Alegerile din Moldova din 2024: O Bătălie pentru Democrație Împotriva Dezinformării</span></li><li><span>Northcrest Developments launches design competition to reimagine 2-km former airport Runway into a vibrant pedestrianized corridor, shaping a new era of placemaking on an international scale</span></li><li><span>The Road to Sustainable Electric Motors for EVs: IDTechEx Analyzes Key Factors</span></li><li><span>Infrared Technology Breakthroughs Paving the Way for a US$500 Million Market, Says IDTechEx Report</span></li><li><span>MegaFair Revolutionizes the iGaming Industry with Skill-Based Games</span></li><li><span>European Commission Evaluates Poland’s Media Adherence to the Right to be Forgotten</span></li><li><span>Global Race for Autonomous Trucks: Europe a Critical Region Transport Transformation</span></li><li><span>Digi Communications N.V. confirms the full redemption of €450,000,000 Senior Secured Notes</span></li><li><span></span></li> <li><span>Global Outlook for the Challenging Autonomous Bus and Roboshuttle Markets</span></li><li><span>Evolving Brain-Computer Interface Market More Than Just Elon Musk’s Neuralink, Reports IDTechEx</span></li><li><a href="https://travelprnews.com/latin-trails-wraps-up-a-successful-3rd-quarter-with-prestigious-lata-sustainability-award-and-expands-conservation-initiatives/travel-press-release/2024/09/25/" rel="noopener nofollow" target="_blank">Latin Trails Wraps Up a Successful 3rd Quarter with Prestigious LATA Sustainability Award and Expands Conservation Initiatives ↗️</a></li><li><span>Astor Asset Management 3 Ltd leitet Untersuchung für potenzielle Sammelklage gegen Ricardo Benjamín Salinas Pliego von Grupo ELEKTRA wegen Marktmanipulation und Wertpapierbetrug ein</span></li><li><span>Digi Communications N.V. announces that the Company’s Romanian subsidiary exercised its right to redeem the Senior Secured Notes due in 2025 in principal amount of €450,000,000</span></li><li><span>Astor Asset Management 3 Ltd Inicia Investigación de Demanda Colectiva Contra Ricardo Benjamín Salinas Pliego de Grupo ELEKTRA por Manipulación de Acciones y Fraude en Valores</span></li><li><span></span></li><li><span>Digi Communications N.V. announced that its Spanish subsidiary, Digi Spain Telecom S.L.U., has completed the first stage of selling a Fibre-to-the-Home (FTTH) network in 12 Spanish provinces</span></li><li><span>Natural Cotton Color lancia la collezione "Calunga" a Milano</span></li><li><span>Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas</span></li><li><span>Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze</span></li><li><span>ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności</span></li><li><span>Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity</span></li><li><span>Digi Communications NV announces the release of H1 2024 Financial Results</span></li><li><span>Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary</span></li><li><span>Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results</span></li><li><span>Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal</span></li><li><span>Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.</span></li><li><span>Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain</span></li><li><span>SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products</span></li><li><span>Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year</span></li> <li><span>Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022</span></li><li><span>Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024</span></li><li><span>Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report</span></li><li><span>Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall</span></li><li><span>SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests</span></li><li><span>WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds</span></li> <li><span>Museum of Unrest: a new space for activism, art and design</span></li><li><span>Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group</span></li><li><span></span></li><li><span>Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026</span></li><li><span>Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024</span></li><li><span>Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group</span></li><li><span>Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report</span></li><li><span>Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results</span></li><li><span>Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024</span></li><li><span>Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report</span></li><li><span>Digi Communications N.V. announces the availability of the 2023 Annual Report</span></li><li><a href="https://travelprnews.com/international-airlines-group-adopts-airline-economics-by-skailark/travel-press-release/2024/05/02/" rel="noopener nofollow" target="_blank">International Airlines Group adopts Airline Economics by Skailark ↗️</a></li><li><span>BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility</span></li><li><span>Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares</span></li><li><span>BevZero South Africa Achieves FSSC 22000 Food Safety Certification</span></li><li><span>Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million</span></li><li><span>Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics</span></li><li><span>driveMybox continues its international expansion: Hungary as a new strategic location</span></li><li><span>Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget</span></li><li><span>Digi Communications NV announces the release of the 2023 Preliminary Financial Results</span></li><li><span>Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results</span></li><li><span>Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София</span></li> <li><span>Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal</span></li><li><span>Digi Communications N.V. Announces the release of the Financial Calendar for 2024</span></li><li><span>Customer Data Platform Industry Attracts New Participants: CDP Institute Report</span></li><li><span>eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir</span></li><li><span>BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology</span></li><li><span>Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares</span></li><li><span>Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses</span></li><li><span>Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию</span></li><li><span>Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights</span></li><li><a href="https://travelprnews.com/north-texas-couple-completes-dream-purchase-of-ourays-iconic-beaumont-hotel/travel-press-release/2023/11/27/" rel="noopener nofollow" target="_blank">North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel</a></li><li><span>Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке</span></li><li><span>Digi Communications NV announces the release of the Q3 2023 Financial Results</span></li><li><span>IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home</span></li><li><span>BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”</span></li><li><span>Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer</span></li><li><span>Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results</span></li><li><span>Jifiti Granted Electronic Money Institution (EMI) License in Europe</span></li><li><span>Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности</span></li><li><span>VRG Components Welcomes New Austrian Independent Agent</span></li><li><span>Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain</span></li><li><span>Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы</span></li><li><a href="https://travelprnews.com/double-digit-growth-in-global-hospitality-industry-for-q4-2023/travel-press-release/2023/09/27/" rel="noopener nofollow" target="_blank">Double digit growth in global hospitality industry for Q4 2023</a></li><li><span>ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market</span></li><li><span>Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland</span></li><li><span>EU-Funded CommuniCity Launches its Second Open Call</span></li><li><span>Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas</span></li><li><span>La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas</span></li><li><span>Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks</span></li><li><span>Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware</span></li><li><span>Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations</span></li><li><span>Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021</span></li><li><span>Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year</span></li><li><span>Digi Communications N.V. announces the availability of the 2022 Annual Report</span></li><li><span>Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts</span></li><li><span>Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство</span></li><li><span>BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility</span></li><li><span>Russian Emigrés Amplify Pleas of “I Want You to Live” through Art</span></li><li><span>Digi Communications NV announces the release of H1 2023 Financial Results</span></li><li><span>Digi Communications NV Announces Investors Call for the H1 2023 Financial Results</span></li><li><span>Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report</span></li><li><span>“Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine</span></li><li><span>Digi Communications N.V. announces the availability of the 2022 Annual Financial Report</span></li><li><a href="https://travelprnews.com/amseindshuttle-nuevo-servicio-de-transporte-que-conecta-el-aeropuerto-de-eindhoven-y-amsterdam/travel-press-release/2023/07/04/" rel="noopener nofollow" target="_blank">“AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam</a></li><li><a href="https://travelprnews.com/un-nuovo-servizio-navetta-amseindshuttle-collega-laeroporto-di-eindhoven-ad-amsterdam/travel-press-release/2023/07/04/" rel="noopener nofollow" target="_blank">Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam</a></li><li><span>Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary</span></li><li><span>Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar</span></li><li><span>iGulu F1: Brewing Evolution Unleashed</span></li><li><span>Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом</span></li><li><span>Hajj Minister meets EU ambassadors to Saudi Arabia</span></li><li><span>Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists</span></li><li><span>Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021</span></li><li><span>Digi Communications N.V. announces the release of the Q1 2023 financial results</span></li><li><span>AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE</span></li><li><span>Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation</span></li><li><span>Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar</span></li><li><span>Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary</span></li><li><span>Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary</span></li><li><span>Patients as Partners Europe Returns to London and Announces Agenda Highlights</span></li><li><span>GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE</span></li><li><span>Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain</span></li><li><span>XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)</span></li><li><span>Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper</span></li> <li><span>Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone</span></li><li><span>Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona</span></li><li><span>Editor's pick archive....</span></li></ul></div></div></div><p>Comments are closed.</p></section> <img class="lazyload" data-src="https://ts2.mm.bing.net/th?q=Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)" alt="Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <section> </section> </article> <div class="text-2xl font-semibold mt-5 mb-5">Top Articles</div> <div class="container-doc"> <a href="https://seagamenight.com/article/beyond-the-bamboo-curtain-new-asian-songs-for-worship/8774" target="_blank" rel="noopener" class="group mb-20 flex flex-col items-center"> <img class="lazyload h-56 object-cover" data-src="https://ts2.mm.bing.net/th?q=Beyond the Bamboo Curtain: New Asian Songs for Worship" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <div class="group-hover:text-primary-500 block font-medium mt-5 text-2xl"> Beyond the Bamboo Curtain: New Asian Songs for Worship </div> </a> <a href="https://seagamenight.com/article/bridging-tradition-and-technology-robotics-and-ai-open-a-new-path-for-classical-indian-music/8774" target="_blank" rel="noopener" class="group mb-20 flex flex-col items-center"> <img class="lazyload h-56 object-cover" data-src="https://ts2.mm.bing.net/th?q=Bridging Tradition and Technology: Robotics and AI Open a New Path for Classical Indian Music" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <div class="group-hover:text-primary-500 block font-medium mt-5 text-2xl"> Bridging Tradition and Technology: Robotics and AI Open a New Path for Classical Indian Music </div> </a> <a href="https://seagamenight.com/article/cross-cultural-comparison-of-successful-aging-definitions-between-chinese-and-hmong-elders-in-the-united-states/8774" target="_blank" rel="noopener" class="group mb-20 flex flex-col items-center"> <img class="lazyload h-56 object-cover" data-src="https://ts2.mm.bing.net/th?q=Cross-cultural comparison of successful aging definitions between Chinese and Hmong elders in the United States" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <div class="group-hover:text-primary-500 block font-medium mt-5 text-2xl"> Cross-cultural comparison of successful aging definitions between Chinese and Hmong elders in the United States </div> </a> </div> <div class="text-2xl font-semibold mt-5 mb-5">Latest Posts</div> <div class="container-doc"> <a href="https://seagamenight.com/article/ron-cook-s-wife-a-deep-dive-into-their-relationship-and-life-together/8774" target="_blank" rel="noopener" class="group mb-20 flex flex-col items-center"> <img class="lazyload h-56 object-cover" data-src="https://ts2.mm.bing.net/th?q=Ron Cook's Wife: A Deep Dive Into Their Relationship And Life Together" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <div class="group-hover:text-primary-500 block font-medium mt-5 text-2xl"> Ron Cook's Wife: A Deep Dive Into Their Relationship And Life Together </div> </a> <a href="https://seagamenight.com/article/wheatland-s-latest-auction-closes-this-weekend-cobbs-mantle-rc-1986-fleer-box/8774" target="_blank" rel="noopener" class="group mb-20 flex flex-col items-center"> <img class="lazyload h-56 object-cover" data-src="https://ts2.mm.bing.net/th?q=Wheatland's Latest Auction Closes This Weekend - Cobbs, Mantle RC, 1986 Fleer Box +" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR42mP8/h8AAvMB+NzmkbcAAAAASUVORK5CYII="/> <div class="group-hover:text-primary-500 block font-medium mt-5 text-2xl"> Wheatland's Latest Auction Closes This Weekend - Cobbs, Mantle RC, 1986 Fleer Box + </div> </a> </div> <div class="text-2xl font-semibold mt-5 mb-5">Recommended Articles</div> <div class="container-doc mb-5"> <ul class="ml-5 list-disc break-all"> <li><a href="https://aftelo.shop/article/der-aufstieg-der-nationalsozialisten" target="_blank" rel="noopener" > Der Aufstieg der Nationalsozialisten </a></li> <li><a href="https://athont.best/article/i-don-t-need-the-grand-duke-s-regret-chapter-29-belle-reservoir" target="_blank" rel="noopener" > I Don’t Need the Grand Duke’s Regret - Chapter 29 - Belle Reservoir </a></li> <li><a href="https://ghostsofnd.com/article/da-vine-joy-randolph-s-oscar-win-is-just-the-start-the-roles-will-get-better-the-money-will-improve" target="_blank" rel="noopener" > Da’Vine Joy Randolph’s Oscar Win Is Just the Start: ‘The Roles Will Get Better, The Money Will Improve’ </a></li> <li><a href="https://guraud.best/article/blog-kanuchi:-kuroki-tsubasa-no-shou" target="_blank" rel="noopener" > Blog Kanuchi: Kuroki Tsubasa No Shou </a></li> <li><a href="https://heavydutydieselcc.com/article/sasaki-to-miyano-official" target="_blank" rel="noopener" > Sasaki to Miyano (Official) </a></li> <li><a href="https://incidi.best/article/matris-all-creatures" target="_blank" rel="noopener" > Matris All Creatures </a></li> <li><a href="https://ledere.cfd/article/daphne-du-maurier-the-bbc-radio-collection-review" target="_blank" rel="noopener nofollow" > ‘Daphne du Maurier - the BBC Radio Collection’ review </a></li> <li><a href="https://lehosa.best/article/don-coscarelli-s-the-beastmaster-1982-swords-sorcery-and-nostalgia-retro-review-pophorror" target="_blank" rel="noopener" > Don Coscarelli's 'THE BEASTMASTER' (1982): Swords, Sorcery, and Nostalgia - Retro Review - PopHorror </a></li> <li><a href="https://limone.cfd/article/choi-si-won-bio-profile-facts-age-girlfriend-ideal-type" target="_blank" rel="noopener" > Choi Si Won - Bio, Profile, Facts, Age, Girlfriend, Ideal Type </a></li> <li><a href="https://mingsh.best/article/antimicrobial-use-and-resistance-in-democratic-republic-of-annals-of-medicine-and-surgery" target="_blank" rel="noopener nofollow" > Antimicrobial use and resistance in Democratic Republic of... : Annals of Medicine and Surgery </a></li> <li><a href="https://nactle.best/article/disney-strait-jacket" target="_blank" rel="noopener" > Disney Strait Jacket </a></li> <li><a href="https://niblen.shop/article/super-mario-party-for-nintendo-switch-nintendo-official-site-for-canada" target="_blank" rel="noopener" > Super Mario Party™ for Nintendo Switch - Nintendo Official Site for Canada </a></li> <li><a href="https://oldedi.sbs/article/snoring-sleep-apnea-causes-treatment-for-arizona-valley-ent" target="_blank" rel="noopener" > Snoring & Sleep Apnea Causes & Treatment for Arizona — Valley ENT </a></li> <li><a href="https://putoma.best/article/what-order-to-watch-miss-granny-2018" target="_blank" rel="noopener" > What Order To Watch Miss Granny (2018) </a></li> <li><a href="https://racter.best/article/like-an-actress-2023-movie-streaming" target="_blank" rel="noopener" > Like An Actress (2023) Movie Streaming </a></li> <li><a href="https://rasrubinetterie.com/article/10-best-survival-games-for-mac-in-2022-m1-and-intel" target="_blank" rel="noopener" > 10 Best Survival Games for Mac in 2022 [M1 and Intel] </a></li> <li><a href="https://paintingandmoreinc.com/article/hair-rollers-suppliers-manufacturers-wholesalers-and-traders-go4worldbusiness-com-page" target="_blank" rel="noopener" > Hair Rollers Suppliers, Manufacturers, Wholesalers and Traders | go4WorldBusiness.com . Page </a></li> <li><a href="https://cabinascristina.com/article/ayumu-kasuga%27s-mail-order-life-car-decal" target="_blank" rel="noopener" > Ayumu Kasuga's Mail Order Life Car Decal </a></li> <li><a href="https://realtyassociateskansas.com/article/57-sims-4-makeup-cc-lipstick-eyeliner-blush-more-we-want-mods" target="_blank" rel="noopener nofollow" > 57+ Sims 4 Makeup CC: Lipstick, Eyeliner, Blush & More - We Want Mods </a></li> <li><a href="https://realmadridar.com/article/these-skincare-devices-will-give-you-spa-like-results-at-home" target="_blank" rel="noopener" > These Skincare Devices Will Give You Spa-Like Results At Home </a></li> <li><a href="https://oharapress.com/article/stratos-4:-logbook-manga-synopsis" target="_blank" rel="noopener" > Stratos 4: Logbook Manga Synopsis </a></li> <li><a href="https://ghigginsfloors.com/article/james-wright-on-linkedin-gallaghertexans" target="_blank" rel="noopener" > James Wright on LinkedIn: #gallaghertexans </a></li> <li><a href="https://katzmoor.com/article/brains-vs-braun-how-about-both-braun-s-series-9-beard-trimmer-reviewed" target="_blank" rel="noopener" > Brains vs. Braun? How About Both? Braun's Series 9 Beard Trimmer, Reviewed </a></li> <li><a href="https://jubileeyc.net/article/thompson-images-of-ritual-mockery-on-greek-vases-dissertation" target="_blank" rel="noopener nofollow" > Thompson: Images of Ritual Mockery on Greek Vases (Dissertation) </a></li> <li><a href="https://embassyhotelbelize.com/article/beacon-of-neyda-renders" target="_blank" rel="noopener" > Beacon Of Neyda Renders </a></li> <li><a href="https://netopenservices.com/article/the-lady%27s-prize-characters-anime" target="_blank" rel="noopener" > The Lady's Prize Characters Anime </a></li> <li><a href="https://izmirneselimuze.com/article/the-magical-lands-cracked-multiplayer" target="_blank" rel="noopener" > The Magical Lands Cracked Multiplayer </a></li> <li><a href="https://telemarketingdotcom.com/article/quest-partners-llc-increases-position-in-u-s-physical-therapy-inc-nyse-usph" target="_blank" rel="noopener" > Quest Partners LLC Increases Position in U.S. Physical Therapy, Inc. (NYSE:USPH) </a></li> <li><a href="https://mpsdn.com/article/utage-menu-stat-displays" target="_blank" rel="noopener nofollow" > Utage Menu/Stat Displays </a></li> <li><a href="https://victoriatz.com/article/a-beauty-editor-tests-magnetic-lashes" target="_blank" rel="noopener" > A Beauty Editor Tests Magnetic Lashes </a></li> <li><a href="https://stenascanpaper.com/article/cheng-yufeng-businesses" target="_blank" rel="noopener" > Cheng Yufeng Businesses </a></li> <li><a href="https://saltcay.net/article/listen-to-hidehiko-kadota" target="_blank" rel="noopener nofollow" > Listen To Hidehiko Kadota </a></li> <li><a href="https://theshoesalon.com/article/ostomy-bags-accessories-market-overall-study-report-2024-2032-salts-healthcare-wellspect-cardinal-health-mckesson-stryker-coloplast-acelity-hollister-medtronic" target="_blank" rel="noopener" > Ostomy Bags Accessories Market Overall Study Report 2024-2032 | Salts Healthcare, Wellspect, Cardinal Health, McKesson, Stryker, Coloplast, Acelity, Hollister, Medtronic </a></li> <li><a href="https://thedeanonnimpo.com/article/max-the-curse-of-brotherhood-im-test-zauberstift-gegen-monsteraffe" target="_blank" rel="noopener" > Max: The Curse of Brotherhood im Test - Zauberstift gegen Monsteraffe </a></li> <li><a href="https://billingsspitbeachhouse.com/article/we-tried-tonnes-of-aluminium-free-deodorants-but-only-these-5-passed-our-rigorous-tests" target="_blank" rel="noopener" > We Tried Tonnes of Aluminium-Free Deodorants, But Only These 5 Passed Our Rigorous Tests </a></li> <li><a href="https://azoresmarlin.com/article/where-did-they-film-beethoven-%E2%80%93-tage-aus-einem-leben-1976" target="_blank" rel="noopener" > Where Did They Film Beethoven – Tage Aus Einem Leben (1976) </a></li> <li><a href="https://l1productions.com/article/norris-defies-orders-to-help-piastri-and-verstappen-loses-the-qatar-pole-to-russell" target="_blank" rel="noopener nofollow" > Norris defies orders to help Piastri and Verstappen loses the Qatar pole to Russell </a></li> <li><a href="https://totallytrotwood.com/article/your-majesty!-anime-air-date" target="_blank" rel="noopener" > Your Majesty! Anime Air Date </a></li> <li><a href="https://kqxs888.org/article/play-mechwarrior-4:-mercenaries-online-for-free" target="_blank" rel="noopener nofollow" > Play Mechwarrior 4: Mercenaries Online For Free </a></li> <li><a href="https://shakiraheaven.com/article/princess-comet-anime" target="_blank" rel="noopener" > Princess Comet (Anime) </a></li> <li><a href="https://sasquatchbrewfest.org/article/12-best-blackhead-removal-tools-for-smoother-skin" target="_blank" rel="noopener" > 12 Best Blackhead Removal Tools for Smoother Skin </a></li> <li><a href="https://basiacostumes.com/article/dinghai-fusheng-records-pink-hair" target="_blank" rel="noopener nofollow" > Dinghai Fusheng Records Pink Hair </a></li> <li><a href="https://adpersonamstyle.com/article/l-intervista-a-lino-guanciale-il-centro" target="_blank" rel="noopener" > L’intervista a Lino Guanciale | Il Centro </a></li> <li><a href="https://koinphotos.com/article/jeu-de-spider-solitaire-en-ligne-100-gratuit" target="_blank" rel="noopener" > Jeu de Spider Solitaire en ligne ⇒ 100% gratuit </a></li> <li><a href="https://babylonianensemble.com/article/top-6-reasons-for-using-vitamin-c-serums" target="_blank" rel="noopener" > Top 6 Reasons for Using Vitamin C Serums </a></li> <li><a href="https://percyboomhaven.com/article/break-the-game-make-the-player-feel-like-they-are-essentially-just-cheating-old-school-runescape-s-biggest-event-is-here-and-it-s-all-about-overpowered-nonsense" target="_blank" rel="noopener" > "Break the game - make the player feel like they are essentially just cheating!": Old School RuneScape's biggest event is here, and it's all about overpowered nonsense </a></li> <li><a href="https://mdsfloor.com/article/global-glove-medical-and-hsn-code-4015110000-export-import-trade-data-buyers-suppliers" target="_blank" rel="noopener nofollow" > Global Glove Medical and HSN Code 4015110000 export import trade data, buyers & suppliers </a></li> <li><a href="https://thosedesigners.com/article/the-children-of-%CE%B1%27s-clan-season-list" target="_blank" rel="noopener" > The Children Of Α's Clan Season List </a></li> <li><a href="https://canaktan.net/article/nico-mastorakis-glasses-brand" target="_blank" rel="noopener" > Nico Mastorakis Glasses Brand </a></li> <li><a href="https://yellowhousearts.org/article/is-ether-vapor-fun-solo" target="_blank" rel="noopener nofollow" > Is Ether Vapor Fun Solo </a></li> <li><a href="https://straightegyptianarabians.com/article/ogden-ut-medical-supply-store-alpine-home-medical" target="_blank" rel="noopener nofollow" > Ogden, UT Medical Supply Store - Alpine Home Medical </a></li> <li><a href="https://mediancer.com/article/i-started-working-a-housekeeping-job-and-ended-up-being-liked-by-the-family-of-the-most-beautiful-girl-in-school.-manga-86" target="_blank" rel="noopener" > I Started Working A Housekeeping Job And Ended Up Being Liked By The Family Of The Most Beautiful Girl In School. Manga 86 </a></li> <li><a href="https://mybangkokpost.com/article/dust-on-the-tongue-2014-english" target="_blank" rel="noopener" > Dust On The Tongue (2014) English </a></li> <li><a href="https://portalmatter.com/article/dd-hokuto-no-ken-ep-10-bg-sub" target="_blank" rel="noopener" > Dd Hokuto No Ken Ep 10 Bg Sub </a></li> <li><a href="https://berkshirevalleypresbychurch.org/article/an-interview-with-director-jack-o-brien-hairspray-to-san-diego-july-6th-we-got-bruce" target="_blank" rel="noopener" > An Interview with Director Jack O’Brien: Hairspray To San Diego July 6th - We Got Bruce! </a></li> <li><a href="https://cairnshillmethodist.org/article/rika-cap-23" target="_blank" rel="noopener nofollow" > Rika Cap 23 </a></li> <li><a href="https://softservices.net/article/moon-of-one-sided-love-doujin" target="_blank" rel="noopener" > Moon Of One Sided Love Doujin </a></li> <li><a href="https://bellevue87.com/article/bible-gateway-passage-jean-3-jean-3-la-bible-du-semeur" target="_blank" rel="noopener" > Bible Gateway passage: Jean 3, Jean 3 - La Bible du Semeur </a></li> <li><a href="https://blueridgefoodbrokers.com/article/black-friday-7-sexy-sins" target="_blank" rel="noopener" > Black Friday 7 Sexy Sins </a></li> <li><a href="https://makeastorybook.com/article/anny-nagellack-nail-polish" target="_blank" rel="noopener" > ANNY Nagellack Nail Polish </a></li> <li><a href="https://zapovedi.org/article/mastering-the-art-of-unjamming-your-dewalt-nail-gun-toolingideas" target="_blank" rel="noopener" > Mastering the Art of Unjamming Your DeWalt Nail Gun - ToolingIdeas </a></li> <li><a href="https://fancydiamondinc.com/article/%EC%84%9C%EB%B6%80%EC%A0%84%EC%84%A0-2015-all-song" target="_blank" rel="noopener nofollow" > 서부전선 (2015) All Song </a></li> <li><a href="https://brannenwoodwinds.com/article/when-is-shuudengo-capsule-hotel-de-joushi-ni-binetsu-tsutawaru-yoru.-in-theaters" target="_blank" rel="noopener" > When Is Shuudengo, Capsule Hotel De, Joushi Ni Binetsu Tsutawaru Yoru. In Theaters </a></li> <li><a href="https://iuifc.org/article/letramentos-visuais-visual-literacies" target="_blank" rel="noopener" > Letramentos visuais / Visual Literacies </a></li> <li><a href="https://disgrafservices.com/article/game-watch-legend-of-zelda-nintendo-switch" target="_blank" rel="noopener" > Game&Watch Legend of Zelda Nintendo Switch </a></li> <li><a href="https://jakubnemecek.com/article/improve-your-dental-hygiene-with-flaus-electric-flosser-beauty-news-nyc-the-first-online-beauty-magazine" target="_blank" rel="noopener" > Improve Your Dental Hygiene with Flaus’ Electric Flosser - Beauty News NYC - The First Online Beauty Magazine </a></li> <li><a href="https://stjopickering.org/article/20-best-lucifers-hammer-of-december-2024" target="_blank" rel="noopener nofollow" > 20 Best Lucifers Hammer of December 2024 </a></li> <li><a href="https://nuttyaboutneopets.com/article/where-is-the-muppets-filmed" target="_blank" rel="noopener" > Where Is The Muppets Filmed </a></li> <li><a href="https://nationalpowerandsignal.com/article/telugu-new-hd-movies-download" target="_blank" rel="noopener" > Telugu New Hd Movies Download </a></li> <li><a href="https://sattlerndt.com/article/mori-girl-fashion-style-50-mori-kei-outfit-ideas-her-style-code" target="_blank" rel="noopener" > Mori Girl Fashion Style & 50 Mori Kei Outfit Ideas - Her Style Code </a></li> <li><a href="https://wagipedia.com/article/slaughterhouse-2001-film" target="_blank" rel="noopener" > Slaughterhouse (2001) Film </a></li> <li><a href="https://heathhen.com/article/what-s-new-on-netflix-what-s-on-netflix" target="_blank" rel="noopener" > What's New on Netflix - What's on Netflix </a></li> <li><a href="https://redcanoebistro.com/article/%D0%B0%D0%BB%D1%91%D1%88%D0%B0-1080p-download" target="_blank" rel="noopener" > Алёша 1080P Download </a></li> <li><a href="https://poeket.com/article/bleach:-thousand-year-blood-war---the-separation-recap-universal-studios" target="_blank" rel="noopener" > Bleach: Thousand-Year Blood War - The Separation Recap Universal Studios </a></li> <li><a href="https://resumecourier.net/article/tetris-forever-switch-review-vooks" target="_blank" rel="noopener nofollow" > Tetris Forever (Switch) Review - Vooks </a></li> <li><a href="https://erestaurantservices.com/article/all-overwatch-2-heroes-and-their-abilities" target="_blank" rel="noopener" > All Overwatch 2 heroes and their abilities </a></li> <li><a href="https://fvpres.com/article/based-on-a-true-story-season-2-recap-episodes-1-8-who-was-the-copycat-killer" target="_blank" rel="noopener nofollow" > 'Based On A True Story' Season 2 Recap (Episodes 1-8): Who Was The Copycat Killer? </a></li> <li><a href="https://nebae.info/article/ichigo-ichie-9-keys-to-embrace-japanese-moments" target="_blank" rel="noopener" > Ichigo Ichie: 9 Keys to Embrace Japanese Moments </a></li> <li><a href="https://coldfolio.info/article/northland-s-new-mobile-ent-clinic-inspired-by-maori-battalion" target="_blank" rel="noopener" > Northland's new mobile ENT clinic inspired by Māori Battalion </a></li> <li><a href="https://sunapartelle.com/article/fall-in-love-with-a-child-paraphilias-forum" target="_blank" rel="noopener" > fall in love with a child : Paraphilias Forum </a></li> <li><a href="https://byjove.net/article/chung-bik-wing-drug-addiction" target="_blank" rel="noopener" > Chung Bik-Wing Drug Addiction </a></li> <li><a href="https://whataboutabout.com/article/all-33-malls-in-auckland-ranked-from-worst-to-best" target="_blank" rel="noopener" > All 33 malls in Auckland ranked from worst to best </a></li> <li><a href="https://walkaboutstudio.com/article/how-to-mute-harvestella" target="_blank" rel="noopener" > How To Mute Harvestella </a></li> <li><a href="https://number7arts.com/article/the-ordinary-didn-t-have-any-black-friday-deals-but-their-sale-includes-this-10-botox-in-a-bottle-anti-aging-serum-that-my-mom-in-her-60s-loves" target="_blank" rel="noopener" > The Ordinary didn't have any Black Friday deals — but their sale includes this $10 'Botox in a Bottle' anti-aging serum that my mom in her 60s loves </a></li> <li><a href="https://floridarealestatesalesinc.com/article/higashi-no-eden-movie-ii-paradise-lost-2" target="_blank" rel="noopener" > Higashi no Eden Movie II: Paradise Lost </a></li> <li><a href="https://chauffeurexec.com/article/michal-dworczyk-about-karol-nawrocki-i-do-not-think-it-is-injustice-but-a-strategy" target="_blank" rel="noopener" > Michał Dworczyk about Karol Nawrocki: I do not think it is injustice, but a strategy </a></li> <li><a href="https://eastshoreaikikai.com/article/is-total-normal-worth-watching" target="_blank" rel="noopener nofollow" > Is Total Normal Worth Watching </a></li> <li><a href="https://gamerhub.abcya.beauty/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener nofollow" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://gamespace.abcya.codes/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://gamespace.frivgames.lol/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://gamerworld.abcya.beauty/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://gameplanet.abcya.run/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://gameplanet.frivgames.rest/article/1000-pack-cotton-buds-extra-value-big-pack" target="_blank" rel="noopener" > 1000 Pack Cotton Buds | Extra Value & Big Pack </a></li> <li><a href="https://ufosdg.org/article/the-story-of-coco-chanel-s-little-black-dress-29secrets" target="_blank" rel="noopener" > THE STORY OF: Coco Chanel's Little Black Dress - 29Secrets </a></li> <li><a href="https://kellyreillyphotography.net/article/lost-planet-2-best-setup" target="_blank" rel="noopener" > Lost Planet 2 Best Setup </a></li> <li><a href="https://tomfmason.net/article/nutrition-facts-for-earnest-eats-earnest-eats-asia-blend-superfood-hot-cereal" target="_blank" rel="noopener nofollow" > Nutrition Facts for Earnest eats - EARNEST EATS, ASIA BLEND SUPERFOOD HOT CEREAL </a></li> <li><a href="https://glenfin.net/article/goku-shop-fr-reviews-check-if-site-is-scam-or-legit-scamadviser" target="_blank" rel="noopener" > goku-shop.fr Reviews | check if site is scam or legit| Scamadviser </a></li> <li><a href="https://heartcatcher.net/article/simon-chong-anorexia" target="_blank" rel="noopener" > Simon Chong Anorexia </a></li> <li><a href="https://syf5.net/article/pure-essential-omega-3-wild-fish-oil-1360mg-epa-dha-1000mg-astaxanthin-180s-the-natural-dispensary" target="_blank" rel="noopener" > Pure & Essential Omega-3 Wild Fish Oil 1360mg EPA & DHA 1000mg & Astaxanthin 180s: The Natural Dispensary </a></li> <li><a href="https://stepstoemployment.net/article/ou-sama-kid-anime-quiz" target="_blank" rel="noopener" > Ou-Sama Kid Anime Quiz </a></li> </ul> </div> <div class="pt-3 bg-white rounded-lg my-0"> <form class="flex justify-center w-full px-5 pt-0 pb-5" target="_top" action="https://seagamenight.com/search-article"> <input aria-label="keyword" type="text" name="keyword" class="search-input w-full" placeholder="Search for articles" /> <button class="search-button" type="submit" value="Submit"> <img width="18" height="18" src="/static-res/img/search.svg?id=b28071f3b9c4778b36f1" alt="Search" /> </button> </form> </div> <div class="text-gray-700 bg-gray-200 rounded px-5 py-4 space-y-2 my-3"> <div class="font-semibold text-center">Article information</div> <p><span class="font-semibold">Author</span>: <span class="vcard"><a class="url fn" href="/">Greg O'Connell</a></span> </p> <p><span class="font-semibold">Last Updated</span>: <span class="posted-on"><time class="entry-date published" datetime="2024-12-03T00:57:56+07:00" itemprop="datePublished">2024-12-03T00:57:56+07:00</time></span> </p> <p><span class="font-semibold">Views</span>: 6146</p> <p><span class="font-semibold">Rating</span>: 4.1 / 5 (42 voted)</p> <p><span class="font-semibold">Reviews</span>: 81% of readers found this page helpful</p> </div> <div class="text-gray-700 bg-gray-200 rounded px-5 py-4 space-y-2 my-3"> <div class="font-semibold text-center">Author information</div> <p><span class="font-semibold">Name</span>: Greg O'Connell</p> <p><span class="font-semibold">Birthday</span>: 1992-01-10</p> <p><span class="font-semibold">Address</span>: Suite 517 2436 Jefferey Pass, Shanitaside, UT 27519</p> <p><span class="font-semibold">Phone</span>: +2614651609714</p> <p><span class="font-semibold">Job</span>: Education Developer</p> <p><span class="font-semibold">Hobby</span>: Cooking, Gambling, Pottery, Shooting, Baseball, Singing, Snowboarding</p> <p><span class="font-semibold">Introduction</span>: My name is Greg O'Connell, I am a delightful, colorful, talented, kind, lively, modern, tender person who loves writing and wants to share my knowledge and understanding with you. </p> </div> </div> </section> </main> <aside class="right-container"> <div class="hidden xl:block sticky top-2 space-y-1"> <div class="text-center " > <ins class="adsbygoogle adsense h-ad4 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <div class="text-center " > <ins class="adsbygoogle adsense h-ad3 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> <div class="text-center " > <ins class="adsbygoogle adsense h-ad2 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> </div> </aside> </div> <div class="text-center sticky top-2 right-2 hidden xl:block flex-shrink-0 " style="width: 160px; height: 600px;" > <ins class="adsbygoogle adsense h-ad4 " data-ad-client="ca-pub-2100455203284867" style="display:block" data-ad-format="auto" data-ad-slot="5425269451" data-full-width-responsive="true" data-adtest="off" > </ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script> </div> </main> <footer class=" bg-white "> <div class="container mx-auto px-5 flex flex-col pt-8 pb-5 text-center sm:text-left xl:px-10"> <div class="flex-wrap sm:flex"> <div class="sm:w-1/2 lg:w-1/5"> <div class="text-sm font-bold text-gray-600 uppercase">NAVIGATION</div> <ul class="mt-4"> <li class="mt-2"> <a href="https://seagamenight.com" title="Home">Home</a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/dmca" title="DMCA">DMCA</a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/privacy-policy" title="Privacy Policy">Privacy Policy</a> </li> </ul> </div> <div class="mt-8 sm:w-1/2 sm:mt-0 lg:w-1/5 lg:mt-0"> <div class="text-sm font-bold text-gray-600 uppercase">DISCOVER</div> <ul class="mt-4"> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/terms-and-conditions" title="Terms And Conditions">Terms And Conditions</a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/cookie-agreement" title="Cookie Agreement">Cookie Agreement</a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/contacts" title="Contacts">Contacts</a> </li> </ul> </div> <div class="mt-8 sm:w-1/2 sm:mt-12 lg:w-1/5 lg:mt-0"> <div class="text-sm font-bold text-gray-600 uppercase">CONTACT US</div> <ul class="mt-4"> <li> <a title="Email Contact Us" href="mailto:dinhthienvan1@gmail.com"> dinhthienvan1@gmail.com </a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/about-us" title="About Us">About Us</a> </li> <li class="mt-2"> <a target="_blank" href="https://seagamenight.com/page/disclaimer" title="Disclaimer">Disclaimer</a> </li> </ul> </div> <div class="mt-8 sm:w-1/2 lg:w-2/5 lg:mt-0 lg:pl-12"> <a href="https://seagamenight.com" class="text-xl font-bold tracking-wider text-primary-500"> Seagamenight </a> <p class="mt-2 text-base text-gray-600 sm:text-justify text-center leading-7"> Zapping through the best free online games ever! With Seagamenight you can play fresh games on any device from school, work - from everywere. Simple. Easy. Fun! <br /> </p> </div> </div> <div class="mt-3 flex items-center flex-col sm:flex-row sm:justify-between" > <p class="text-sm text-gray-600 flex-bas"> © 2024 Seagamenight. All Rights Reserved. </p> </div> </div> </footer> </div> <div class='code-block code-block-1' style='opacity: 0.01278399879; top: 150px; position: fixed; z-index: 9995; width: 728px; height: 250px; text-align: center; left: 36%; transform: translate(-50%, -50%); opacity: 0.01874718879;'> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script>  <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-2100455203284867" data-ad-slot="5425269451" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> <div class='code-block code-block-2' style='opacity: 0.01278399879; top: 150px; position: fixed; z-index: 9995; width: 728px; height: 250px; text-align: center; left: 36%; transform: translate(-50%, -50%); opacity: 0.01874718879;'> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script>  <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-2100455203284867" data-ad-slot="5425269451" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> <div class='code-block code-block-3' style='opacity: 0.01278399879; top: 150px; position: fixed; z-index: 9995; width: 728px; height: 250px; text-align: center; left: 36%; transform: translate(-50%, -50%); opacity: 0.01874718879;'> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script>  <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-2100455203284867" data-ad-slot="5425269451" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> <div class='code-block code-block-4' style='opacity: 0.01278399879; top: 550px; position: fixed; z-index: 9995; width: 300px; height: 300px; text-align: center; left: 50%; transform: translate(-50%, -50%);'> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script>  <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-2100455203284867" data-ad-slot="5425269451" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> <div class='code-block code-block-5' style='opacity: 0.01278399879; top: 550px; position: fixed; z-index: 9995; width: 300px; height: 300px; text-align: center; left: 50%; transform: translate(-50%, -50%);'> <script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-2100455203284867" crossorigin="anonymous"></script>  <ins class="adsbygoogle" style="display:block" data-ad-client="ca-pub-2100455203284867" data-ad-slot="5425269451" data-ad-format="auto" data-full-width-responsive="true"></ins> <script> (adsbygoogle = window.adsbygoogle || []).push({}); </script></div> <div x-data="{ open: false }"> <button class="hidden px-4 py-2 text-white bg-blue-500 rounded select-none no-outline focus:shadow-outline" @click="open = true" id="adblock">adblock</button> <div class="fixed z-10 inset-0 overflow-y-auto" aria-labelledby="modal-title" role="dialog" aria-modal="true" x-show="open" style="display: none" id="aaaaa-modal"> <div class="flex items-end justify-center min-h-screen pt-4 px-4 pb-20 text-center sm:block sm:p-0"> <div class="fixed inset-0 bg-gray-500 bg-opacity-95 transition-opacity" aria-hidden="true"></div> <span class="hidden sm:inline-block sm:align-middle sm:h-screen" aria-hidden="true"></span> <div class="inline-block align-bottom bg-white rounded-lg text-left overflow-hidden shadow-xl transform transition-all sm:my-8 sm:align-middle sm:max-w-lg sm:w-full"> <div class="bg-white px-4 pt-5 pb-4 sm:p-6 sm:pb-4"> <div class="sm:flex sm:items-start"> <div id="ic-warning" class="mx-auto flex-shrink-0 flex items-center justify-center h-12 w-12 rounded-full bg-red-100 sm:mx-0 sm:h-10 sm:w-10"> <svg class="h-6 w-6 text-red-600" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"> <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z" /> </svg> </div> <div class="mt-3 text-center sm:mt-0 sm:ml-4 sm:text-left"> <div class="text-lg leading-6 font-medium text-gray-900" id="modal-title"> We notice you're using an ad blocker </div> <div class="mt-2"> <p class="text-sm text-gray-500"> Without advertising income, we can't keep making this site awesome for you. </p> </div> </div> </div> </div> <div class="bg-gray-50 px-4 py-3 sm:px-6 flex-center"> <button onclick="location.reload();" type="button" class="w-full inline-flex justify-center rounded-md border border-transparent shadow-sm px-4 py-2 bg-red-600 text-base font-medium text-white hover:bg-red-700 focus:outline-none focus:ring-2 focus:ring-offset-2 focus:ring-red-500 sm:ml-3 sm:w-auto sm:text-sm"> I understand and have disabled ad blocking for this site </button> </div> </div> </div> </div> </div> </body> </html>

CINXE.COM

Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation (2024)